FibroGen (FGEN) Projected to Post Quarterly Earnings on Tuesday

FibroGen (NASDAQ:FGEN) is anticipated to issue its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($4.01) per share and revenue of $1.64 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, November 10, 2025 at 5:00 PM ET.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($3.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.25) by ($1.13). The business had revenue of $1.30 million during the quarter, compared to the consensus estimate of $2.88 million. On average, analysts expect FibroGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FibroGen Stock Performance

FibroGen stock traded up $0.07 during mid-day trading on Tuesday, reaching $11.08. 2,603 shares of the company were exchanged, compared to its average volume of 69,458. FibroGen has a twelve month low of $4.50 and a twelve month high of $21.94. The firm’s 50-day simple moving average is $11.42 and its two-hundred day simple moving average is $8.92. The firm has a market cap of $44.81 million, a PE ratio of -29.16 and a beta of 0.76.

Analyst Ratings Changes

FGEN has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroGen in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $43.00 price target on shares of FibroGen in a report on Wednesday, September 24th. Finally, Wall Street Zen raised FibroGen from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, FibroGen presently has an average rating of “Hold” and an average price target of $43.00.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.